Therapeutic angiogenesis with exosomal microRNAs: an effectual approach for the treatment of myocardial ischemia

Moghiman, Toktam; Barghchi, Bita; Esmaeili, Seyed‐Alireza; Shabestari, Mahmood; Tabaee, Seyedeh Samaneh; Momtazi‐Borojeni, Amir Abbas

doi:10.1007/s10741-020-10001-9

Cited by 43 publications

(32 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The composition of exosomal cargo is very diverse and includes a wide range of immunosuppressive and immunostimulatory proteins, chemokines, cytokines, cellular receptors, lipids, as well as different nucleic acids such as micro-RNAs and circular RNAs. [62][63][64] Tumor cells can actively produce large levels of exosomes enriched in cancer-promoting cellular contents, such as immunosuppressive proteins like PD-L1, mRNAs, and micro-RNAs, that participate in cancer development and metastasis, through dysregulating antitumor or protumor immunity responses and promoting drug resistance. [65][66][67] Of note, tumor-secreted exosomes contain PD-L1 presented both on the surface and within exosome particles.…”

Section: Activity Of Exosomal Pd-l1mentioning

confidence: 99%

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Yin

et al. 2021

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

Exosomes, as the main group of extracellular vesicles, are biologically active lipid-bilayer vesicles that are naturally released from different types of normal or tumor cells. These vesicles play an important role in intercellular communication and influence the extracellular environment and the immune system. Emerging evidence demonstrates that cancer-derived exosomes are enriched in immunosuppressive proteins, such as the programmed death-ligand 1 (PD-L1). PD-L1 and its receptor programmed cell death protein 1 (PD-1) are the key immune checkpoint molecules that promote tumor progression via negative regulation of immune responses. PDL-1 is highly expressed on the surface of tumor cells and binds to PD-1 on the surface of activated T cells, leading to suppression of T cells, which consequently enables cancer cells to escape antitumor immunity. Currently, there are several Food and Drug Administration-approved monoclonal antibodies blocking PD-1/PD-L1 interaction, which are clinically used for cancer treatment. However, despite impressive treatment outcomes, some patients show poor response to PD-1/PD-L1 blockade. Of note, tumor-derived exosomes containing PD-L1 can recapitulate the effect of cell-surface PD-L1. There is evidence that reveals a significant association between levels of circulating exosomal PD-L1 and rate of response to anti-PD-1/PD-L1 antibody therapy. The present article reviews the role of exosomal PDL-1 in the therapeutic resistance to anti-PD-1/PD-L1 treatment. Importantly, it is suggested that the removal of exosomal PDL-1 could serve as a therapeutic adjuvant for enhancing the efficacy of anti-PD-1/PD-L1 therapy in patients with cancer.

show abstract

Section: Activity Of Exosomal Pd-l1mentioning

confidence: 99%

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Yin

et al. 2021

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Coding and non-coding RNAs, proteins, antigen-presenting molecules and DNA are the main compositions of exosomes. [20][21][22] Microvesicles consist of bilayer lipids containing mRNAs, miRNAs as well as lipids and cytosol. Because of their size and composition, exosomes are considered to be more important in the field of tissue engineering and regenerative medicine.…”

Section: The B I Ology and Pathophys Iology Of E X Tr Acellul Ar Ve S I Cle S In Oamentioning

confidence: 99%

Extracellular Vesicles in chondrogenesis and Cartilage regeneration

Zhao

Cheng

Zhou

et al. 2021

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Cartilage is a hydrated tissue with no vascular and neural networks.They are divided into three major groups: hyaline, fibrous and elastic cartilages. Hyaline cartilage is the most frequent form and is found in synovial joints, ribs, nose, trachea, bronchi, etc 1 The main roles of this articular hyaline cartilage are to tolerate bone load and forming a lubricant environment to enable joint movement. 2 Extracellular matrix (ECM) synthesized by chondrocytes constitutes the main part of each cartilage. Collagen type II is the most frequent ECM molecule in hyaline cartilage and accounts for 90%-95% of total collagen molecules. 3,4 Collagen II forms filamentous structures with collagen IX, responsible for cartilage tensile and shear stress. Proteoglycans, such as aggrecan, and glycosaminoglycans (GAG), such as chondroitin sulphate, are the other components of the articular cartilage ECM. 5,6 The integrity of ECM is vital for the normal function of cartilage. Therefore, changes in ECM elements and composition are the main feature of cartilage diseases. 7

show abstract

“…Exosomes are secreted from cells via exocytosis and absorbed by target cells, resulting in the transfer of biological signals (Yang et al, 2018). Many types of cells have been shown to secrete exosomes, such as B cells, epithelial cells, fibroblasts, and a variety of tumor cells (Mehryab et al, 2020;Moghiman et al, 2020;Peng et al, 2020). As important mediators of intercellular communication, the functions of exosomes are dependent on their cargo profile, which includes miRNAs, messenger RNAs, DNA, and proteins that contribute to both physiological functions and the pathophysiologies of a variety of diseases, including PF (Colombo et al, 2014;Akbari and Rezaie, 2020;Cocozza et al, 2020;Khalaj et al, 2020).…”

Section: Exosomes and Epithelial Mesenchymal Transitionmentioning

confidence: 99%

Therapeutic Potential of Exosomes in Pulmonary Fibrosis

Xie

Zeng

2020

Front. Pharmacol.

View full text Add to dashboard Cite

Pulmonary fibrosis is closely associated with the recruitment of fibroblasts from capillary vessels with damaged endothelial cells, the epithelial mesenchymal transition (EMT) of type II alveolar epithelial cells, and the transformation of fibroblasts to myofibroblasts. Recent studies suggest that EMT is a key factor in the pathogenesis of pulmonary fibrosis, as the disruption of EMT-related effector molecules can inhibit the occurrence and development of PF. With the numerous advancements made in molecular biology in recent years, researchers have discovered that exosomes and their cargos, such as miRNAs, lncRNAs, and proteins, can promote or inhibit the EMT, modulate the transformation of fibroblasts into myofibroblasts, contribute to the proliferation of fibroblasts and promote immunoregulatory and mitochondrial damage during pulmonary fibrosis. Exosomes are key factors regulating the differentiation of bone marrow mesenchymal stem cells (BMSCs) into myofibroblasts. Interestingly, exosomes derived from BMSCs under pathological and physiological conditions may promote or inhibit the EMT of type II alveolar epithelial cells and the transformation of fibroblasts into myofibroblasts to regulate pulmonary fibrosis. Thus, exosomes may become a new direction in the study of drugs for the treatment of pulmonary fibrosis.

show abstract

Therapeutic angiogenesis with exosomal microRNAs: an effectual approach for the treatment of myocardial ischemia

Cited by 43 publications

References 63 publications

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Extracellular Vesicles in chondrogenesis and Cartilage regeneration

Therapeutic Potential of Exosomes in Pulmonary Fibrosis

Contact Info

Product

Resources

About